Neurofibromatosis Clinical Trial
Official title:
Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis
Verified date | April 2017 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a prospective study through the NF clinic at Massachusetts General Hospital that will examine the relationship between psychosocial factors, health literacy, and satisfaction with the medical visit in adults with NF1, NF2, and Schwannomatosis. A total of 89 participants will be enrolled in the study.
Status | Completed |
Enrollment | 86 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Age 18 or older 2. Can read and speak English at or above the 6th grade level 3. Diagnosis of neurofibromatosis type 1, neurofibromatosis type 2, or schwannomatosis Exclusion Criteria: 1. Severe active or untreated major mental illness that would interfere with study participation, to be determined at the discretion of the study investigator (e.g. untreated psychosis or suicidality) 2. Unable or unwilling to participate 3. Unable or unwilling to complete psychological assessments online via the REDCap or Assessment Center systems. |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Age, Gender, Ethnicity, and Race of Patients with NF | The questionnaire asks for the patient's age, gender, ethnicity, and race as part of the basic demographics. | Baseline (pre-medical visit) | |
Other | Visual Analog Health Scale | Measures one's current health on a scale from 0 ("very poor") to 10 ("very good"). | Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours. | |
Other | Learning Disabilities of Patients with NF | This question asks patients if they have ever been diagnosed with a learning disability. | Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours. | |
Other | First Time at NF Clinic | This question asks the patient if it's their first time at the MGH NF clinic. | Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours. | |
Primary | Patient Reported Outcomes Measurement Information System (PROMIS) | A battery of measures assessing: depression, anxiety, anger, fatigue, pain behavior and interference, physical function, satisfaction with discretionary social activities, satisfaction with social roles, and health literacy. | Baseline (pre-medical visit) | |
Primary | Functional, Communicative and Critical Health Literacy (FFFHL) scale | Measures one's health literacy, the capacity of individuals to access, understand, and use health information to make informed and appropriate health-related decisions. | Baseline (pre-medical visit) | |
Primary | Medical Interview Satisfaction Scale (MISS) | Measures patient satisfaction with individual doctor-patient consultations. | Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours. | |
Primary | Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey | Asks patients to report on and evaluate their experiences with health care. This survey covers topics that are important to consumers and focus on aspects of quality that consumers are best qualified to assess, such as the communication skills of providers and ease of access to health care services. | Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00754780 -
Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1
|
Phase 2 | |
Completed |
NCT00589784 -
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
|
Phase 2 | |
Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
Completed |
NCT01673009 -
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
|
Phase 2 | |
Recruiting |
NCT00598351 -
Natural History Study of Patients With Neurofibromatosis Type 2
|
||
Completed |
NCT02298270 -
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype
|
N/A | |
Terminated |
NCT01402817 -
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
|
Phase 2 | |
Completed |
NCT02101736 -
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
|
Phase 2 | |
Completed |
NCT01633008 -
Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain
|
Early Phase 1 | |
Terminated |
NCT04461886 -
A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I
|
Phase 3 | |
Completed |
NCT01275586 -
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
|
Early Phase 1 | |
Active, not recruiting |
NCT01140360 -
Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
|
Phase 1/Phase 2 | |
Completed |
NCT02211768 -
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
|
Phase 1 | |
Completed |
NCT00508235 -
Quality of Friendships in Children With Neurofibromatosis
|
N/A | |
Completed |
NCT01639950 -
Validating Pain Scales in Children and Young Adults
|